Prime Medicine, Inc. (PRME) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts PRME Hot Sheet
Join SI Premium – FREE
Prime Medicine, Inc. (NASDAQ: PRME) reported Q2 EPS of ($0.41), $0.02 better than the analyst estimate of ($0.43). Revenue for the quarter came in at $1.11 million versus the consensus estimate of $0 .
For earnings history and earnings-related data on Prime Medicine, Inc. (PRME) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Calix, Inc. (CALX) Tops Q3 EPS by 3c; offers guidance
- People Incorporated (PPLI) Misses Q3 EPS by 896c
- Inspire Medical Systems (INSP) Tops Q3 EPS by 5c, Beats on Revenue; Offers FY26 Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
